|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003241,
umls-concept:C0003872,
umls-concept:C0021499,
umls-concept:C0034656,
umls-concept:C0036043,
umls-concept:C0599724,
umls-concept:C1274040,
umls-concept:C1275555,
umls-concept:C1448177,
umls-concept:C1456820,
umls-concept:C1521801,
umls-concept:C2353893
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2009-4-7
|
|
pubmed:abstractText |
To assess the efficacy and safety of golimumab in patients with active psoriatic arthritis (PsA).
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0004-3591
|
|
pubmed:author |
pubmed-author:BeutlerAnnaA,
pubmed-author:GladmanDafnaD,
pubmed-author:Gomez-ReinoJuanJ,
pubmed-author:KavanaughArthurA,
pubmed-author:KruegerGerald GGG,
pubmed-author:MackMichaelM,
pubmed-author:McInnesIainI,
pubmed-author:MeasePhilipP,
pubmed-author:MudivarthySurekhaS,
pubmed-author:PappKimK,
pubmed-author:VisvanathanSudhaS,
pubmed-author:ZrubekJulieJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
60
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
976-86
|
|
pubmed:dateRevised |
2010-8-23
|
|
pubmed:meshHeading |
pubmed-meshheading:19333944-Adult,
pubmed-meshheading:19333944-Antibodies, Monoclonal,
pubmed-meshheading:19333944-Antirheumatic Agents,
pubmed-meshheading:19333944-Antitubercular Agents,
pubmed-meshheading:19333944-Arthritis, Psoriatic,
pubmed-meshheading:19333944-Disability Evaluation,
pubmed-meshheading:19333944-Female,
pubmed-meshheading:19333944-Humans,
pubmed-meshheading:19333944-Injections, Subcutaneous,
pubmed-meshheading:19333944-Male,
pubmed-meshheading:19333944-Middle Aged,
pubmed-meshheading:19333944-Motor Activity,
pubmed-meshheading:19333944-Placebos,
pubmed-meshheading:19333944-Quality of Life,
pubmed-meshheading:19333944-Treatment Outcome,
pubmed-meshheading:19333944-Tuberculosis, Pulmonary,
pubmed-meshheading:19333944-Tumor Necrosis Factor-alpha
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study.
|
|
pubmed:affiliation |
University of California, San Diego, La Jolla, CA 92093-0943, USA. akavanaugh@ucsd.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
